Winchester, MA, United States of America

Alfredo C Castro

This inventor holds 114 USPTO granted patents and 30 published patent applications, plus 5 CIPO patents and 24 EPO patents, primarily in AHR Inhibitors (CPC class C07D471-04). Top assignees: Infinity Pharmaceuticals, Inc., Ikena Oncology, Inc., Infinity Discovery, Inc.. Active years: 2001-2025.

USPTO Granted Patents = 114 (Patent Applications = 30)

% Patents Active = 64.9

CIPO Patents = 5 (Patent Applications = 26)

EPO Patents = 24 (Patent Applications = 41)

Average Co-Inventor Count = 4.5

ph-index = 20

Forward Citations = 1,684(Granted Patents)

Forward Citations (Not Self Cited) = 1,248(Dec 10, 2025)

Inventors with similar research interests:

🔬 See more inventors

Location History:

Weburn, MA (US) (2005)
Winchester, MA (US) (2003 - 2023)
Woburn, MA (US) (2001 - 2024)
Somerville, MA (US) (2020 - 2024)

Company Filing History:

63 out of 108

Infinity Pharmaceuticals, Inc.

Infinity Discovery, Inc.

Cyteir Therapeutics, Inc.

patents

6. 2 out of 1,855

Sanofi-A Ventis Deutschland Gmbh

Aventis Pharma Deutschland, Gmbh

patents

9. 1 out of 5

Biogen Idec Hemophilia Inc.

Millennium Pharmaceuticals Limited

patents

13. 1 out of 14

Syntonix Pharmaceuticals, Inc.

patents

14. 1 out of 834,411

Other

patents

Years Active: 2001-2025

Loading Chart...

Areas of Expertise:

AHR Inhibitors

RAD51 Inhibitors

Heterocyclic Compounds

Polymorphic Compounds

MEK Inhibitors

TEAD Inhibitors

Indole Compounds

Cyclopamine Analogs

Combinations of Inhibitors

Solid Forms

Chemical Compositions

Kinase Modulation

114 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12459895 - MEK inhibitors and uses thereof (2025-11-04),

2. 12295962 - Polymorphic compounds and uses thereof (2025-05-13),

3. 12162884 - Solid forms of (R)-N-(2-(5-fluoropyridin-3-yl)-8-isopropylpyrazolo[1,5-a] [1,3,5]triazin-4-yl)-2,3,4,9-tetrahydro-1H-carbazol-3-amine as aryl hydrocarbon receptor (AHR) inhibitors (2024-12-10),

4. 12152032 - Heterocyclic compounds and uses thereof (2024-11-26),

5. 12077542 - Indole AHR inhibitors and uses thereof (2024-09-03),

6. 12064419 - Methods of using RAD51 inhibitors for treatment of pancreatic cancer (2024-08-20),

7. 12030876 - Aryl hydrocarbon receptor (AHR) agonists and uses thereof (2024-07-09),

8. 11925651 - TEAD inhibitors and uses thereof (2024-03-12),

9. 11878958 - MEK inhibitors and uses thereof (2024-01-23),

10. 11760728 - Tead inhibitors and uses thereof (2023-09-19),

11. 11608329 - Aryl hydrocarbon receptor (AHR) agonists and uses thereof (2023-03-21),

12. 11607404 - Combinations of RAD51 and PARP inhibitors (2023-03-21),

13. 11602527 - Methods of use of cyclopamine analogs (2023-03-14),

14. 11591339 - Solid forms of (R)-N-(2-(5-fluoropyridin-3-yl)-8-isopropylpyrazolo[ 1,5-a][1,3,5]triazin-4-yl)-2,3,4,9-tetrahydro-1H-carbazol-3-amine maleate as aryl hydrocarbon receptor (AHR) inhibitors (2023-02-28),

15. 11555026 - AHR inhibitors and uses thereof (2023-01-17),

Title: The Innovation Journey of Inventor Alfredo C Castro

Introduction:

Alfredo C Castro, a prolific inventor based in Winchester, MA, has made significant contributions to the field of pharmaceuticals and biotechnology. With an impressive portfolio of 106 patents, his groundbreaking work has shaped the landscape of MEK and Tead inhibitors.

Latest Patents:

Among his latest patents is the development of MEK inhibitors and their versatile applications. These inhibitors have paved the way for new avenues in cancer research and treatment. Additionally, the Tead inhibitors introduced by Castro demonstrate the innovative spirit driving his work towards addressing complex medical challenges.

Career Highlights:

Alfredo C Castro has made notable contributions to companies such as Infinity Pharmaceuticals, Inc., where his expertise has been instrumental in driving forward cutting-edge research and development initiatives. His association with Infinity Discovery, Inc. further underscores his commitment to innovation and scientific advancement in the pharmaceutical industry.

Collaborations:

Throughout his career, Castro has collaborated with esteemed professionals in the field, including colleagues such as Martin R Tremblay and Michael J Grogan. These collaborations have not only enhanced the scope of his work but have also fostered a culture of shared knowledge and expertise within the scientific community.

Conclusion:

Inventor Alfredo C Castro stands as a visionary in the realm of pharmaceutical innovations, with a rich tapestry of patents reflecting his commitment to pushing the boundaries of scientific discovery. His dedication to developing MEK and Tead inhibitors underscores his passion for driving impactful change in the field, shaping the future of healthcare and biotechnology.